EGFR and neoplasm: Aptamer-antibody conjugates or “oligobody”, such as aptamer against VEGF linked to anti-cotinine antibody, anti-EGFR aptamer linked either to anti-epidermal growth factor receptor 2 (ErbB2) compact antibody or to an immunomodulatory (anti-PD-L1) antibody, have promising distribution into solid tumors, activate T cells against tumor cells and increase anticancer efficiency [10,22].